QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Theratechnologies Stock Price, News & Analysis (NASDAQ:THTX)

$1.70
+0.26 (+18.06%)
(As of 11/28/2023 ET)
Compare
Today's Range
$1.43
$1.70
50-Day Range
$0.89
$2.18
52-Week Range
$0.88
$8.84
Volume
61,508 shs
Average Volume
114,693 shs
Market Capitalization
$41.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

THTX stock logo

About Theratechnologies Stock (NASDAQ:THTX)

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

THTX Stock Price History

THTX Stock News Headlines

Theratechnologies (NASDAQ:THTX) Shares Up 13.3%
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Theratechnologies Announces Operational Update
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Earnings Outlook For Theratechnologies
Theratechnologies Files SBLA For F8 Formulation Of Tesamorelin To FDA
Biopharma Firm Completes Reverse Stock Split
Theratechnologies (TSX: TH)
Theratechnologies: Fiscal Q2 Earnings Snapshot
See More Headlines
Receive THTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/26/2023
Today
11/28/2023
Fiscal Year End
11/30/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:THTX
Employees
144
Year Founded
1993

Profitability

Net Income
$-47,240,000.00
Pretax Margin
-35.92%

Debt

Sales & Book Value

Annual Sales
$79.73 million
Book Value
($0.93) per share

Miscellaneous

Free Float
N/A
Market Cap
$41.14 million
Optionable
Not Optionable
Beta
0.93

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Paul Lévesque (Age 59)
    President, CEO & Director
    Comp: $1.31M
  • Mr. Philippe Dubuc M.B.A. (Age 56)
    MBA, Senior VP & CFO
    Comp: $449.76k
  • Mr. Jocelyn Lafond L.L.M. (Age 55)
    LL.B., General Counsel & Corporate Secretary
    Comp: $325.86k
  • Dr. Christian Marsolais Ph.D. (Age 60)
    Senior VP & Chief Medical Officer
    Comp: $466.81k
  • Mr. John Leasure (Age 58)
    Global Commercial Officer
    Comp: $513.95k
  • Hon. Andre Dupras M.Sc. (Age 59)
    Vice President of Human Resources














THTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Theratechnologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" THTX shares.
View THTX analyst ratings
or view top-rated stocks.

How have THTX shares performed in 2023?

Theratechnologies' stock was trading at $3.5312 at the start of the year. Since then, THTX shares have decreased by 51.9% and is now trading at $1.70.
View the best growth stocks for 2023 here
.

Are investors shorting Theratechnologies?

Theratechnologies saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 34,000 shares, a decline of 82.6% from the October 31st total of 195,400 shares. Based on an average daily trading volume, of 332,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the company's shares are short sold.
View Theratechnologies' Short Interest
.

When is Theratechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our THTX earnings forecast
.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (NASDAQ:THTX) released its earnings results on Tuesday, September, 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.46. The firm earned $20.86 million during the quarter. During the same period last year, the business posted ($0.32) EPS.

When did Theratechnologies' stock split?

Shares of Theratechnologies reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What guidance has Theratechnologies issued on next quarter's earnings?

Theratechnologies issued an update on its FY 2023 earnings guidance on Tuesday, September, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82.00 million-$85.00 million, compared to the consensus revenue estimate of $83.64 million.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX).

Who are Theratechnologies' major shareholders?

Theratechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (3.32%), Worth Venture Partners LLC (0.81%), Cyndeo Wealth Partners LLC (0.43%), Stifel Financial Corp (0.37%), National Bank of Canada FI (0.28%) and Hamilton Capital LLC (0.18%).

How do I buy shares of Theratechnologies?

Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Theratechnologies have any subsidiaries?
The following companies are subsidiares of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.
Read More
This page (NASDAQ:THTX) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -